IRIS
CIARDIELLO, DAVIDE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 265
EU - Europa 260
AS - Asia 12
Totale 537
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 261
IE - Irlanda 141
IT - Italia 81
DE - Germania 19
CN - Cina 6
FI - Finlandia 6
CA - Canada 4
IN - India 4
CZ - Repubblica Ceca 3
AT - Austria 2
FR - Francia 2
GB - Regno Unito 2
GI - Gibilterra 2
BE - Belgio 1
GR - Grecia 1
HK - Hong Kong 1
JP - Giappone 1
Totale 537
Salva come PNG Salva come JPEG
Città #
Dublin 135
Chandler 60
New York 38
Naples 28
Bremen 10
Ashburn 9
Princeton 8
Roxbury 8
Cambridge 7
Beijing 6
Boardman 5
Lappeenranta 5
Battipaglia 4
Caserta 3
Colle di Val d'Elsa 3
Elora 3
Ercolano 3
Munich 3
Pozzuoli 3
Anantapur 2
Andover 2
Brdo 2
Fairfield 2
Milan 2
Pune 2
San Mateo 2
San Nicola la Strada 2
Strasbourg 2
Vienna 2
Antea 1
Berlin 1
Brno 1
Brussels 1
Castellammare Di Stabia 1
Central 1
Cercola 1
Des Moines 1
Helsinki 1
Los Angeles 1
Matera 1
Medford 1
Miami 1
Monmouth Junction 1
Paola 1
Seattle 1
Somma Vesuviana 1
Toronto 1
Torre del Greco 1
Trumbull 1
Yokohama 1
Totale 382
Salva come PNG Salva come JPEG
Nome #
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 56
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 44
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 42
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 36
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 36
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 32
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 28
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer 27
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 26
Immunotherapy in advanced anal cancer: Is the beginning of a new era? 26
Clinical management of metastatic colorectal cancer in the era of precision medicine 26
Beyond N staging in colorectal cancer: Current approaches and future perspectives 24
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 21
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 21
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 20
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 17
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 16
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 16
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 13
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 11
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 11
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 6
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 5
Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson 2
Totale 562
Salva come PNG Salva come JPEG
Categoria #
all - tutte 2.879
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.879
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217 3 0 0 0 0 3 0 0 0 0 1 0
2021/202258 0 0 0 0 2 0 0 0 2 2 30 22
2022/2023303 16 5 9 26 27 26 3 23 139 3 22 4
2023/2024194 25 9 8 16 51 50 7 6 8 6 8 0
Totale 562